Investors & Media

Transformative science, targeted medicines

We are working to advanceĀ a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

Analyst coverage

Analyst coverage

Firm Analyst
Canaccord Genuity Inc.
Arlinda Lee, Ph.D.
Cowen and Company
Marc Frahm, Ph.D.
Deutsche Bank
Konstantinos Aprilakis, M.D.
Goldman, Sachs & Co.
Salveen Richter
Guggenheim Securities
Michael Schmidt, Ph.D.
Jefferies
Eun Yang, Ph.D
Leerink Partners
Andrew Berens, M.D.
JMP Securities
Under transition
Morgan Stanley
David Lebowitz
Piper Jaffray
Chris Raymond
Raymond James
Dane Leone
Robert W. Baird
Michael Ulz
Wedbush PacGrow Lifes Siences
David Nierengarten, Ph.D.
Blueprint Medicines Corporation is followed by the analysts listed on this page. Please note that any opinions, estimates or forecasts regarding Blueprint Medicines Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Blueprint Medicines Corporation or its management. Blueprint Medicines Corporation does not by its reference here or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.